Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) With Cardiomyopathy
Latest Information Update: 19 Jul 2023
At a glance
- Drugs Patisiran (Primary)
- Indications Cardiomyopathies; Transthyretin-related hereditary amyloidosis
- Focus Adverse reactions; Expanded access
- Sponsors Alnylam Pharmaceuticals
Most Recent Events
- 14 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 22 Aug 2022 New trial record